Kelley Moffett

Stories

FDA clears combined use of Solventum's Restrata matrix and V.A.C. therapy

Active

The U.S. Food and Drug Administration cleared Solventum to use its Restrata synthetic tissue matrix with its V.A.C. negative pressure wound therapy on October 19, 2026, the first clearance combining the two. Clinicians can place a fully synthetic, resorbable scaffold under a vacuum dressing that stays on for up to seven days.

Updated 4 hours ago

Notable Quotes

"We're focused on delivering meaningful innovation that helps healthcare providers address clinical challenges and supports patients as they return to daily life."

from FDA clears combined use of Solventum's Restrata matrix and V.A.C. therapy · Updated 4 hours ago

"By combining Restrata Matrix's technology with our trusted V.A.C. Therapy, we're giving clinicians an effective way to streamline care and support better patient outcomes."

from FDA clears combined use of Solventum's Restrata matrix and V.A.C. therapy · Updated 4 hours ago